Table 1.
Baseline Characteristics.
| Switch group (n=18) | non-switch group (n=19) | p value | |||
|---|---|---|---|---|---|
| Male | 18 | 19 | 1.000 | ||
| Median age, years | 44 | ( 38 - 68) | 39 | ( 24 - 54) | 0.423 |
| Japanese, (%) | 17 | ( 94 ) | 19 | 1.000 | |
| Median weight, kg | 67 | ( 59 - 76) | 67 | ( 50 - 89) | 0.423 |
| Median TDF/FTC use, months (IQR) | 48 | ( 24 - 64) | 33 | ( 14 , 63) | 0.463 |
| Median CD4+cells, /µL (IQR) | 551 | ( 347 , 690) | 568 | ( 507 , 754) | 0.525 |
| CD4+ cells bellow 200 /µL(%) | 2 | ( 11 ) | 2 | ( 11 ) | 1.000 |
| Comorbidity | |||||
| Dyslipidemia, (%) | 12 | ( 67 ) | 10 | ( 53 ) | 0.508 |
| Type II diabetes mellitus, (%) | 0 | ( 0 ) | 2 | ( 11 ) | 0.486 |
| HCV infection, (%) | 2 | ( 11 ) | 1 | ( 5 ) | 0.604 |
| Hemophilia B, (%) | 2 | ( 11 ) | 0 | ( 0 ) | 0.230 |
| Smoker, (%) | 8 | ( 44 ) | 8 | ( 42 ) | 1.000 |
| Third antiretroviral agent, (%) | |||||
| RAL | 8 | ( 44 ) | 9 | ( 47 ) | 1.000 |
| EFV | 6 | ( 33 ) | 6 | ( 32 ) | 1.000 |
| ATV/r | 2 | ( 11 ) | 2 | ( 11 ) | 1.000 |
| LPV/r | 1 | ( 6 ) | 1 | ( 5 ) | 1.000 |
| DRV/r | 1 | ( 6 ) | 1 | ( 5 ) | 1.000 |
| Stable lipid-lowering treatments at baseline, (%) | |||||
| Statins | 1 | ( 6 ) | 1 | ( 5 ) | 1.000 |
| Fibrates | 2 | ( 11 ) | 1 | ( 5 ) | 0.604 |
| Median lipid parameters, mg/dL (IQR) | |||||
| LDL | 92 | ( 81 , 105) | 97 | ( 83 , 107) | 0.456 |
| HDL | 43 | ( 36 , 49) | 41 | ( 37 , 50) | 0.860 |
| TG | 166 | ( 100 , 212) | 126 | ( 109 , 159) | 0.284 |
| TC | 159 | ( 143 , 178) | 157 | ( 146 , 172) | 0.203 |
p values for comparison between the switch group and the non-switch group are determined by Fisher’s exact tests or by Mann-Whitney’s U tests. Abbreviations: IQR: interquartile range, HCV: hepatitis C virus, TDF/FTC: tenofovir/emtricitabine, RAL: raltegravir, EFV: efavirenz, ATV: atazanavir, /r: ritonavir, LPV: lopinavir, DRV: darunavir, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglyceride, TC: total cholesterol